- €2.52bn
- €2.68bn
- €1.40bn
- 82
- 30
- 74
- 70
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 15.09 | ||
| PEG Ratio (f) | 1.57 | ||
| EPS Growth (f) | 10.62% | ||
| Dividend Yield (f) | 0.53% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.42 | ||
| Price to Tang. Book | 4.89 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.8 | ||
| EV to EBITDA | 9.75 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 15.69% | ||
| Return on Equity | 14.95% | ||
| Operating Margin | 15.53% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 934.2 | 1,063.96 | 1,216.19 | 1,246.9 | 1,397.38 | 1,482.04 | 1,564.57 | 8.29% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +46.95 | +37.47 | +9.06 | -1.93 | +20.66 | +10.31 | +11.22 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Virbac SA is a France-based veterinarian pharmaceutical company that specializes in the development and production of vaccines and medicines for domestic animals and livestock. Its production centers are located in France, Australia, the United States, Mexico, Vietnam, Brazil and South Africa. Its development efforts focus mainly on formulating drugs designed to prevent or cure certain animal diseases. Its product portfolio encompasses pet medications such as pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds and rodents, as well as livestock medications including pest control drugs and antibiotics intended for cattle, sheep, pigs and poultry. It also offers food and electronic identification chips for pets.
Directors
- Marie-Helene Dick-madelpuech CHM (56)
- Sebastien Huron CEO (50)
- Habib Ramdani DCE (45)
- Marc Bistuer DCE (52)
- Pierre Madelpuech VCH (60)
- Francesca Cortella DHR
- Bertrand Havrileck MGB
- Nathalie Pollet MGB
- Hubert Trentesaux MGB
- Sylvie Gueguen DRC (56)
- Solene Madelpuech DRC (27)
- Olivier Bohuon IND (62)
- Philippe Capron IND (63)
- Cyrille Petit IND (50)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 1st, 1984
- Public Since
- January 1st, 1985
- No. of Employees
- 5,620
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Euronext - Paris- Shares in Issue
- 8,374,594
- Address
- 13e rue LID - BP 27, CARROS, 06511
- Web
- https://corporate.virbac.com/
- Phone
- +33 492087100
- Auditors
- Deloitte & Associes
Upcoming Events for VIRP
Half Year 2025 Virbac SA Earnings Release
Half Year 2025 Virbac SA Earnings Presentation
Q3 2025 Virbac SA Corporate Sales Release
Similar to VIRP
AB Science SA
Euronext - Paris
Advicenne SA
Euronext - Paris
Aelis Farma SA
Euronext - Paris
Boiron SA
Euronext - Paris
DBV Technologies SA
Euronext - Paris
FAQ
What is the Virbac SA share price?
As of Today at 23:59 UTC, shares in Virbac SA are trading at €301.15. This share price information is delayed by 15 minutes.
How has the Virbac SA share price performed this year?
Shares in Virbac SA last closed at €301.15 and the price had moved by -13.09% over the past 365 days. In terms of relative price strength the Virbac SA share price has underperformed the FTSE Global All Cap Index by -15.26% over the past year.
What are the analyst and broker recommendations for Virbac SA?
The overall consensus recommendation for Virbac SA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Virbac SA dividend yield?
The Virbac SA dividend yield is 0.48% based on the trailing twelve month period.
Does Virbac SA pay a dividend?
Last year, Virbac SA paid a total dividend of €1.45, and it currently has a trailing dividend yield of 0.48%. We do not have any data on when Virbac SA is to next pay dividends.
When does Virbac SA next pay dividends?
We do not have data on when Virbac SA is to next pay dividends. The historic dividend yield on Virbac SA shares is currently 0.48%.
How do I buy Virbac SA shares?
To buy shares in Virbac SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Virbac SA?
As of the previous close price of €301.15, shares in Virbac SA had a market capitalisation of €2.52bn.
Where are Virbac SA shares listed?
Here are the trading details for Virbac SA:
- Country of listing: France
- Exchange: PAR
- Ticker Symbol: VIRP
What kind of share is Virbac SA?
Based on an overall assessment of its quality, value and momentum Virbac SA is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Virbac SA share price forecast for 2025?
The analyst consensus target price for shares in Virbac SA is €380.30. That is 26.28% above the last closing price of €301.15.
Analysts covering Virbac SA currently have a consensus Earnings Per Share (EPS) forecast of €19.27 for the next financial year.
Find out moreWhat is the trend in the Virbac SA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Virbac SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -15.28%.
As of the last closing price of €301.15, shares in Virbac SA were trading -9.22% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Virbac SA PE Ratio?
The Virbac SA PE ratio based on its reported earnings over the past 12 months is 15.09. The shares last closed at €301.15.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Virbac SA?
Virbac SA's management team is headed by:
- Marie-Helene Dick-madelpuech - CHM
- Sebastien Huron - CEO
- Habib Ramdani - DCE
- Marc Bistuer - DCE
- Pierre Madelpuech - VCH
- Francesca Cortella - DHR
- Bertrand Havrileck - MGB
- Nathalie Pollet - MGB
- Hubert Trentesaux - MGB
- Sylvie Gueguen - DRC
- Solene Madelpuech - DRC
- Olivier Bohuon - IND
- Philippe Capron - IND
- Cyrille Petit - IND